报价延迟最少15分钟:2025/11/17 17:21 EST
盘后时段
|
||||
|
21.64 
|
|
|
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
21.64
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-7.58/0.25
|
|
企业价值
1.07B
|
| 资产负债 |
|
每股账面净值
8.68
|
| 现金流量 |
|
现金流量率
0.10
|
| 损益表 |
|
收益
1.08M
|
|
每股收益
--
|
|
同行比较
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
报价延迟最少15分钟：2025/11/17 17:21 EST
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Septerna Inc is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by a proprietary Native Complex Platform. Its industrial-scale platform aims to unlock the full potential of GPCR therapies. The group discovery and development of a pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic disease. Its pipeline includes SEP-786 (PTH1R), SEP-631 (MRGPRX2), TSHR, GLP-1R, GIPR, and GCGR. |
